Consistent DNA Hypomethylations in Prostate Cancer.

Area of Science:

• Oncology
• Epigenetics
• Genomics

Background:

• Prostate cancer (PCa) affects 1.4 million men globally, with current screening and treatment facing benefit-harm imbalances.
• Declining PCa mortality is linked to prostate-specific antigen (PSA) screening, but new recommendations question its widespread use.
• There is an urgent need for advanced diagnostic and prognostic tools for early PCa detection and personalized therapy.

Purpose of the Study:

• To investigate an epigenetic screening approach using Methylated DNA Immunoprecipitation (MeDIP) for PCa.
• To identify novel diagnostic and prognostic biomarkers for early and reliable PCa assessment.
• To develop a new epigenetic tumor classification system for PCa.

Main Methods:

• Utilized Methylated DNA Immunoprecipitation (MeDIP) for epigenetic screening.
• Analyzed three PCa sample cohorts to identify differentially methylated genes.
• Employed computational biology to focus on single CpG-enriched DNA probes and identify tumor cell-specific differential methylated CpG dinucleotide signatures (TUMS).

Main Results:

• Identified consistently differential methylated DNA segments in PCa samples.
• Discovered specific genes, including NOTCH3, CDK2AP1, KLK4, and ADAM15, associated with hypomethylated CpG islands.
• Revealed short, consistently present differential methylated CpG-rich DNA fragments (TUMS) across all tumors.

Conclusions:

• The identified TUMS can aid in the early discrimination of PCa.
• This epigenetic approach shows potential for a new PCa tumor classification system.
• The findings support the development of new tools for personalized PCa therapy and monitoring.